Fate Therapeutics Inc (NASDAQ: FATE) kicked off on Monday, down -2.48% from the previous trading day, before settling in for the closing price of $3.23. Over the past 52 weeks, FATE has traded in a range of $1.63-$8.83.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 87.14% over the past five years. While this was happening, its average annual earnings per share was recorded -0.05%. With a float of $94.87 million, this company’s outstanding shares have now reached $98.63 million.
Let’s look at the performance matrix of the company that is accounted for 181 employees. In terms of profitability, gross margin is -55.61%, operating margin of -1587.28%, and the pretax margin is -1426.67%.
Fate Therapeutics Inc (FATE) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Fate Therapeutics Inc is 16.69%, while institutional ownership is 93.17%. The most recent insider transaction that took place on Aug 06 ’24, was worth 2,678. In this transaction Director of this company sold 633 shares at a rate of $4.23, taking the stock ownership to the 8,669 shares. Before that another transaction happened on Aug 06 ’24, when Company’s Director proposed sale 633 for $4.23, making the entire transaction worth $2,678.
Fate Therapeutics Inc (FATE) Latest Financial update
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -0.46 earnings per share (EPS), higher than consensus estimate (set at -0.57) by 0.11. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.44 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -0.05% per share during the next fiscal year.
Fate Therapeutics Inc (NASDAQ: FATE) Trading Performance Indicators
Take a look at Fate Therapeutics Inc’s (FATE) current performance indicators. Last quarter, stock had a quick ratio of 9.18. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 29.12.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.71, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach -1.65 in one year’s time.
Technical Analysis of Fate Therapeutics Inc (FATE)
Fate Therapeutics Inc (NASDAQ: FATE) saw its 5-day average volume 1.08 million, a negative change from its year-to-date volume of 2.23 million. As of the previous 9 days, the stock’s Stochastic %D was 77.95%. Additionally, its Average True Range was 0.21.
During the past 100 days, Fate Therapeutics Inc’s (FATE) raw stochastic average was set at 9.77%, which indicates a significant decrease from 60.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.65% in the past 14 days, which was lower than the 78.93% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.49, while its 200-day Moving Average is $4.69. Nevertheless, the first resistance level for the watch stands at $3.24 in the near term. At $3.33, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.42. If the price goes on to break the first support level at $3.07, it is likely to go to the next support level at $2.98. The third support level lies at $2.89 if the price breaches the second support level.
Fate Therapeutics Inc (NASDAQ: FATE) Key Stats
The company with the Market Capitalisation of 358.72 million has total of 113,832K Shares Outstanding. Its annual sales at the moment are 63,530 K in contrast with the sum of -160,930 K annual income. Company’s last quarter sales were recorded 6,770 K and last quarter income was -38,430 K.
